← Back to Screener
NanoViricides Inc. (NNVC)
Price$1.38
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)5.19%
Price vs S&P 500 (4W)-10.96%
VGM Score57.57
Market Capitalization$31.44M
All Metrics
Book Value / Share (Quarterly)$0.42
P/TBV (Annual)3.12x
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)13.97%
EPS (TTM)$-0.44
10-Day Avg Trading Volume3.72M
EPS Excl Extra (TTM)$-0.44
EPS (Annual)$-0.74
ROI (Annual)-57.77%
Cash / Share (Quarterly)$0.15
ROA (Last FY)-50.83%
EBITD / Share (TTM)$-0.41
ROE (5Y Avg)-52.73%
Cash Flow / Share (Annual)$-0.51
P/B Ratio3.43x
P/B Ratio (Quarterly)2.15x
Net Income / Employee (Annual)$-1,227,100
Net Interest Coverage (TTM)-109.25x
ROA (TTM)-81.59%
EPS Incl Extra (Annual)$-0.74
Current Ratio (Annual)1.28x
Quick Ratio (Quarterly)3.02x
3-Month Avg Trading Volume0.69M
52-Week Price Return-7.38%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.41
52-Week High$2.23
EPS Excl Extra (Annual)$-0.74
CapEx CAGR (5Y)41.62%
Tangible BV CAGR (5Y)-19.57%
26-Week Price Return13.11%
Quick Ratio (Annual)1.19x
13-Week Price Return48.98%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.17x
Enterprise Value$28.22M
Book Value / Share Growth (5Y)-28.34%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.09
3-Month Return Std Dev104.49%
Net Income / Employee (TTM)$-1,155,900
ROE (Last FY)-57.77%
Net Interest Coverage (Annual)-1.58x
EPS Basic Excl Extra (Annual)$-0.74
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.44
ROI (TTM)-92.69%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.43
Price vs S&P 500 (52W)-31.75%
Year-to-Date Return22.12%
5-Day Price Return-17.86%
EPS Normalized (Annual)$-0.74
ROA (5Y Avg)-46.67%
Month-to-Date Return-22.47%
Cash Flow / Share (TTM)$-0.71
EBITD / Share (Annual)$-0.71
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-52.06%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.44
P/TBV (Quarterly)2.23x
P/B Ratio (Annual)2.99x
Book Value / Share (Annual)$0.45
Price vs S&P 500 (13W)40.73%
Beta1.76x
Revenue / Share (TTM)$0.00
ROE (TTM)-92.69%
52-Week Low$0.85
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NNVCNanoViricides Inc. | — | — | C | $1.38 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Nanoviricides is a nano-biopharmaceutical company developing antiviral therapeutics for life-threatening viral infections using proprietary nanomedicine technologies. The company builds its pipeline through internal research programs and strategic in-licensing partnerships. This platform-based approach targets areas of significant unmet need in viral disease treatment.